Inhibrx Biosciences Inc.
INBXHealthcare|Biotechnology|US
$84.52
+4.24 (+5.28%)
DCF Value
$0.74
Cash / Share
$8.51
About
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Stock Price
+4.4%(1Y)
1M
-8.9%
3M
-4.7%
6M
-37.1%
YTD
+7.0%
1Y
+7.0%
3Y
+343.0%
5Y
+89.9%
Pipeline Summary
7 total trials4
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 4Active: 1Terminated: 1Completed: 1
Active Trials (5)
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766Solid Tumor
Phase 1Phase 2Recruiting
Enrollment: 340 participants
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
Phase 2Active
Enrollment: 206 participants
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT06353997Triple Negative Breast Cancer
Phase 2Recruiting
Enrollment: 12 participants
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933Ewing Sarcoma
Phase 1Recruiting
Enrollment: 411 participants
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Phase 3Recruiting
Enrollment: 450 participants
Key Facts
Market Cap$1.24B
Employees109 (-30% YoY)
CEOMark Lappe
IPO DateMay 29, 2024
Beta4.04
52-Week Range$57.3 – $155.29
Avg Volume299,387
ExchangeNASDAQ
Websiteinhibrx.com
Ownership
Float74.4%
Shares Outstanding14.7M
Recent Insider Trades
Lappe MarkBUY
Oct 14, 2026100 shares @ $85.76
Lappe MarkBUY
Oct 14, 20262,470 shares @ $85.00
Lappe MarkBUY
Oct 14, 20262,470 shares @ $84.07
Lappe MarkBUY
Oct 14, 2026100 shares @ $85.76
Lappe MarkBUY
Oct 14, 20262,451 shares @ $85.00
Peers
Recent News
Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Oct 27, 2026 · defenseworld.net
Inhibrx Announces Participation in Upcoming Scientific Conferences
Oct 13, 2026 · prnewswire.com
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
Oct 5, 2026 · defenseworld.net
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Oct 2, 2026 · marketbeat.com
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
Sep 30, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:15 AM